RT Journal Article
SR Electronic
T1 Significance of Circulating Galectin-3 in Patients with Pancreatobiliary Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4979
OP 4986
VO 37
IS 9
A1 TATSUO SHIMURA
A1 MASAHIKO SHIBATA
A1 KENJI GONDA
A1 YASUHIDE KOFUNATO
A1 RYO OKADA
A1 TERUHIDE ISHIGAME
A1 TAKASHI KIMURA
A1 AKIRA KENJO
A1 KOJI KONO
A1 SHIGERU MARUBASHI
YR 2017
UL http://ar.iiarjournals.org/content/37/9/4979.abstract
AB Background/Aim: Pancreatobiliary cancer is a disease associated with a dismal prognosis and limited treatment options. The aim of the present study was to clarify the usefulness of circulating galectin-3 in pancreatobiliary cancer. Patients and Methods: We examined serum galectin-3 concentrations in 45 patients with pancreatobiliary cancer. Receiver operating characteristic curves were utilized to evaluate the accuracy of circulating galectin-3 to discriminate pancreatobiliary cancer patients from controls and predict the prognostic outcomes. Results: Circulating galectin-3 had diagnostic value at the cut-off level of 6.2 ng/ml, and the patients' overall survival was predictable at the cut-off level of 10.3 ng/ml. Furthermore, circulating galectin-3 ≥10.3 ng/ml was an independent prognostic marker in pancreatobiliary cancer. Regarding biliary cancer, higher galectin-3 was associated with malnutrition. On the other hand, regarding pancreatic cancer, higher galectin-3 levels were associated with higher inflammatory parameters. Conclusion: Galectin-3 can be a useful biomarker in patients with pancreatobiliary cancer.